Chavarot Nathalie

Néphrologue, Transplantation rénale, hôpital européen Georges Pompidou, Paris, France

[SFT Transplantation @SFTfrancophone]

⚠️ Suite à des publications sur le prélèvement d'organes d'un patient non décédé aux USA, la SFT rappelle dans cet article de @nicolasberrod pour @le_Parisien que le diagnostic de mort encéphalique est beaucoup plus sécurisé en France, où cette situation serait donc impossible !

[Dorry Segev @Dorry_Segev]

donating a kidney is safer than it's ever been -- mortality from donor nephrectomy now one-third of what it was a decade ago, less than 1 in 10,000 -- spread the word!

https://t.co/h7gIC9yazx

[CJ Néphro @CJNephro]

URGENT - Demande de remplacement pour le Centre Hospitalier d'Agen-Nérac https://t.co/ox91ULAHPj

[Nuno Moreira Fonseca @MoreiraFonseca_]

Highlighting the lack of evidence and the significant differences in usage across countries, this paper sheds light on our diverse practices. 🏥🔍  @NahidTabibzadeh
https://t.co/ywkuWVJMqz

[Nathan Peiffer-Smadja @nathanpsmad]

🔥 Nous recherchons un/une cadre de santé ds le Service Maladies Infectieuses et Tropicales @hopitalbichat @APHP

Très bonne ambiance, activité variée et passionnante, ds un joli pavillon de @hopitalbichat

N'hésitez pas à postuler / partager 🙏
👇
https://t.co/DpZooq3dlD

[NDT @NDTsocial]

Efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients on chronic dialysis

🔓https://t.co/QPqL7qtZCU

[Société de Physiologie et de Biologie Intégrative @SocPhysBioInt]

🚨 #JobAlert
Assistant spécialiste aux Explorations Fonctionnelles Rénales @hopitalbichat dès novembre 2024
👉 DFG, exploration des troubles phosphocalciques, hydro-électrolytiques...
👉 HTA (IIR et résistante, centre d'Excellence Européen)
👉 Infos et contact: DM @EmmaVP5

[Agence de la biomédecine @ag_biomedecine]

💚Le 22 juin, c'était la Journée mondiale du don d'organes. Et jamais le don d’organes n’avait fait autant parler de lui.

Médias, entreprises, grand public, associations, institutions et pro de santé : vous n'avez jamais été si nombreux à vous mobiliser ! 📢

En un mot : merci !

[Marc-Olivier Timsit, MD, PhD @UrologieParis]

Mais @iledefrance , c’est aussi un taux d’opposition après décès de plus de 50%.
Si on avait un taux proche de nos voisins espagnols par exemple (~15%) nous aurions ASSEZ d’organes chaque année pour greffer TOUS les nouveaux patients inscrits sur liste d’attente dans l’année.

[Nature Medicine @NatureMedicine]

Now at #ATC2024Philly : A prospective observational study including 2,882 kidney allograft recipients from 14 centers in Europe and the US shows that cell-free DNA can be used to detect kidney allograft rejection @AlexandreLoupy @olivieraubert https://t.co/f7LJO06d6h

[Scott Isaacs @scottisaacsmd]

The SELECT trial on semaglutide for weight loss in obesity without diabetes! Weight loss was sustained over 4 years, semaglutide led to weight loss of -10.2%, reduced waist circumference by -7.7 cm, and improved waist-to-height ratio by -6.9%. #obesity #weightloss #semaglutide #cardiovascularhealth
https://t.co/LZ12xqMuPN

[NEJM @NEJM]

The factor Xa inhibitor reversal agent andexanet reduced expansion of intracerebral hemorrhages caused by factor Xa inhibitors but resulted in more thrombotic events than usual care. Read the full ANNEXA-I trial results: https://t.co/2lut1AszcR

[NEJM @NEJM]

Presented at #HeartFailure2024:

Among patients with symptomatic obstructive hypertrophic cardiomyopathy, treatment with aficamten led to a greater increase in peak oxygen consumption than placebo at 6 months. Full SEQUOIA-HCM phase 3 trial results: https://t.co/8M0wEtJ96d

[Nahid Tabibzadeh @NahidTabibzadeh]

Excited to share this research, supported by @com_SFNDT and @AgenceRecherche and published in @Arch_Pharm
In patients on lithium treatment, polyuria levels correlate with dosage. But what about distal nephron remodeling and microcystic nephropathy? 1/2
https://t.co/ZAxXzuNjIk

[The Lancet @TheLancet]

Semaglutide—a new treatment for obesity-related heart failure with preserved ejection fraction?

1️⃣ Pooled analysis of the placebo-controlled STEP-HFpEF and STEP-HFpEF DM trials: https://t.co/X4COYs6TxM
2️⃣ Linked Comment: https://t.co/gBetzV0Eik

[NEJM @NEJM]

Among patients with obesity-related heart failure with preserved ejection fraction & type 2 diabetes, semaglutide produced greater reductions in symptoms, physical limitations & body weight than placebo at 1 year. Full STEP-HFpEF DM trial results: https://t.co/TbIZ7t391g

#ACC24

[Kamar Nassim @KamarNassim]

Happy to share our paper just released in @KIReports showing that systematic screening for DSAs is useless in low risk immunological patients. However, it should be done if clinically indicated (sensitization event or impaired kidney function) @CHUdeToulouse

[KDIGO @goKDIGO]

KDIGO is pleased to announce the publication of the 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD).

Read the news release: https://t.co/kXzi5xxCvK
Download the guideline: https://t.co/wA8RRI90j9
Read the guideline in Kidney International: https://t.co/VHIZL34ls8

The KDIGO 2024 CKD Guideline was co-chaired by @adeeralevin and @KidneysRU. The Executive Summary will be published in the April 2024 issue of @Kidney_Int.

“We are thrilled to publish this eagerly anticipated update, which comes during a transformative period in nephrology, offering new hope for people living with kidney disease," said Dr. Levin. “Recent advancements in GFR evaluation, risk prediction, and the arrival of novel treatments are poised to enhance CKD prognosis and management. We also hope the guideline’s emphasis on multidisciplinary teamwork, patient engagement, and a holistic, evidence-based approach to care will help catalyze positive change, resulting in more coordinated CKD care management worldwide. By integrating the latest evidence and expert consensus, we aim to empower healthcare professionals, and patients with actionable recommendations to optimize patient outcomes and enhance quality of life.”

“As Co-Chairs, we would like to recognize the outstanding efforts of the Guideline Work Group and extend our thanks to the Evidence Review Team from Johns Hopkins, without whom this guideline would not have been possible," said Dr. Stevens. "The Work Group was diverse, multinational, highly experienced, and exceptionally committed, and we are grateful for their contributions to both this guideline and to global nephrology.”

[Wisit Cheungpasitporn MD FACP | FASN | FAST @wisit661]

☀️Impact of Induction Therapy on the Risk of PTLD in Kidney Transplant Recipients with Donor-Recipient EBV Mismatch -American Journal of Transplantation @napatlee1 @wisit661 @AttiehRose @NephMao @ShennenMao ⁦@MayoClinicNeph⁩ 🙂🙏🏻 @amjtransplant https://t.co/7CSNXeJQXU

[American Journal of Transplantation @amjtransplant]

Original Article by Iske et al, "Transplanting old organs promotes senescence in young recipients"

https://t.co/3Jm3pyCp5b